FCCC LOGO Faculty Publications
Singh LR , Gupta S , Honig NH , Kraus JP , Kruger WD
Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70
PLoS Genet. 2010 Jan;6(1) :e1000807
PMID: 20066033    PMCID: PMC2795852   
Back to previous list
Missense mutant proteins, such as those produced in individuals with genetic diseases, are often misfolded and subject to processing by intracellular quality control systems. Previously, we have shown using a yeast system that enzymatic function could be restored to I278T cystathionine beta-synthase (CBS), a cause of homocystinuria, by treatments that affect the intracellular chaperone environment. Here, we extend these studies and show that it is possible to restore significant levels of enzyme activity to 17 of 18 (94%) disease causing missense mutations in human cystathionine beta-synthase (CBS) expressed in Saccharomyces cerevisiae by exposure to ethanol, proteasome inhibitors, or deletion of the Hsp26 small heat shock protein. All three of these treatments induce Hsp70, which is necessary but not sufficient for rescue. In addition to CBS, these same treatments can rescue disease-causing mutations in human p53 and the methylene tetrahydrofolate reductase gene. These findings do not appear restricted to S. cerevisiae, as proteasome inhibitors can restore significant CBS enzymatic activity to CBS alleles expressed in fibroblasts derived from homocystinuric patients and in a mouse model for homocystinuria that expresses human I278T CBS. These findings suggest that proteasome inhibitors and other Hsp70 inducing agents may be useful in the treatment of a variety of genetic diseases caused by missense mutations.
Singh, Laishram R Gupta, Sapna Honig, Nicholaas H Kraus, Jan P Kruger, Warren D CA06927/CA/NCI NIH HHS/United States HL57299/HL/NHLBI NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States PLoS genetics PLoS Genet. 2010 Jan;6(1):e1000807. Epub 2010 Jan 8.